Results for this period
Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue increased due to higher demand for products covered by the innovative new drug price maintenance system, the inclusion of the RS virus vaccine in the routine vaccination program, stronger sales of new products and other offerings, recommended sales of generic drugs, heightened health awareness and the recovery in demand for going out, higher unit prices, and the inclusion of シグニ as a newly consolidated subsidiary. Operating profit declined due to changes in the product mix, higher rebates and center fees, rising personnel, energy and delivery costs, external warehouse rental costs, and consulting expenses related to the tender offer for PALTAC shares. Interim net income attributable to owners of the parent increased due to the higher ownership interest in PALTAC.
None
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥1,969,620 million (YoY +3.8%) |
| Operating profit | ¥24,321 million (YoY -3.0%) |
| Ordinary income | ¥32,665 million (YoY -4.7%) |
| Profit attributable to owners of the parent | ¥23,027 million (YoY +4.2%) |
| Net income per share | ¥112.49 |
| Operating Margin | 1.23% |
| Equity ratio | End of the current fiscal period 31.2% / End of previous period 33.9% |
| Total assets | ¥1,972,088 million |
| Net assets | ¥616,409 million |
| Cash flows from operating activities | ¥33,097 million |
| Cash flows from investing activities | ¥-24,737 million |
| Cash flows from financing activities | ¥-28,214 million |
| Cash and cash equivalents at end of period | ¥266,684 million |
| Full-year earnings forecast | Net Sales ¥3,944,000 million (YoY +3.3%) / Operating profit ¥53,500 million (YoY +0.6%) / Ordinary income ¥67,500 million (YoY -10.9%) / Net income ¥53,000 million (YoY +24.6%) |
| Annual Dividend Forecast | ¥66 → ¥88 |
| Segment revenue | Wholesale business for prescription pharmaceuticals and other products ¥1,272,459 million (YoY +4.7%), Wholesale business for cosmetics, daily necessities and over-the-counter pharmaceuticals ¥634,749 million (YoY +1.5%), Related businesses, including wholesale of veterinary pharmaceuticals and food-processing raw materials ¥64,498 million (YoY +10.0%) |
| Segment profit | Wholesale business for prescription pharmaceuticals and other products ¥12,582 million (YoY +30.1%), Wholesale business for cosmetics, daily necessities and over-the-counter pharmaceuticals ¥11,026 million (YoY -20.6%), Related businesses, including wholesale of veterinary pharmaceuticals and food-processing raw materials ¥1,910 million (YoY +41.1%) |
| Depreciation and amortization | ¥9,011 million |
| Impairment loss | ¥45 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of property, plant and equipment ¥148 million, Gain on sales of investment securities ¥6,242 million, Other ¥25 million / Extraordinary loss Loss on disposal and sale of non-current assets ¥389 million, Impairment loss ¥45 million, Loss on valuation of investment securities ¥427 million, Other ¥67 million |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | Acquisition and cancellation of treasury shares. At a meeting of the Board of Directors held on 23 October 2026, the Company resolved to acquire up to 4,000,000 common shares for a maximum of ¥10 billion from 6 November 2026 through 31 March 2027, and to cancel all shares acquired. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors, securities analysts and news organizations |
| Issued Shares at Period-End | 215,975,042 shares |
| Treasury Shares at Period-End | 11,276,811 shares |
| Factors Behind Changes in Business Performance | Revenue increased due to higher demand for products covered by the innovative new drug price maintenance system, the inclusion of the RS virus vaccine in the routine vaccination program, stronger sales of new products and other offerings, recommended sales of generic drugs, heightened health awareness and the recovery in demand for going out, higher unit prices, and the inclusion of シグニ as a newly consolidated subsidiary. Operating profit declined due to changes in the product mix, higher rebates and center fees, rising personnel, energy and delivery costs, external warehouse rental costs, and consulting expenses related to the tender offer for PALTAC shares. Interim net income attributable to owners of the parent increased due to the higher ownership interest in PALTAC. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to higher demand for products covered by the wholesale pharmaceuticals business, the inclusion of the RS virus vaccine in the routine vaccination program, and stronger sales of new products and generic drugs. Operating profit declined due to changes in the product mix, higher rebates and center fees paid to customers, rising personnel, energy and delivery costs, and consulting expenses related to the tender offer for PALTAC shares. The increase in the ownership interest in PALTAC contributed to the increase in interim net income attributable to owners of the parent.